Current Transplantation Reports

, Volume 5, Issue 4, pp 327–333 | Cite as

Utilizing Donors with Hepatitis C Antibody Positivity and Negative Nucleic Acid Testing

  • Kimberly A. Brown
  • Mona Hassan
Liver (D Mulligan, Editor)
Part of the following topical collections:
  1. Topical Collection on Liver



The demand for organs in the USA exceeds supply resulting in high mortality for patients awaiting transplantation. To increase the pool of available organs, the transplant community is investigating the safety and utility of organs previously considered high risk. Guidelines currently advocate for the use of hepatitis C antibody, nucleic acid testing (NAT)-negative organs in hepatitis C–positive recipients. However, data is limited regarding outcomes of using such grafts in hepatitis C–negative recipients.

Purpose of Review

The purpose of this paper is to review the literature on utilizing hepatitis C virus (HCV)-positive NAT-negative livers and to determine if utilizing direct-acting antivirals lowers the risk of HCV transmission regardless of the recipient’s HCV status.

Recent Findings

The current literature demonstrates that the overall risk of transmission of HCV with the use of these organs in HCV-negative recipients is low and that risk is increased with high-risk donors that died from IVDA overdose.


Direct-acting antivirals are highly effective in treating HCV and lowering the risk of transmission. Therefore, we should reconsider utilizing these organs in HCV-positive recipients.


Liver transplantation Extended criteria donors Nucleic acid test HCV antibody-positive/NAT-negative donors HCV transplant transmission risk Hepatitis C–positive donors Occult hepatitis C 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Szabo E, Lotz G, Paska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol Oncol Res: POR. 2003;9(4):215–21.CrossRefGoogle Scholar
  2. 2.
    World Health Assembly, 63: Viral hepatitis – report by the secretariat 2010. (last accessed April 19, 2017).
  3. 3.
    Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang. 2012;102:82–90.CrossRefGoogle Scholar
  4. 4.
    Pereira B. Levey A. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51:981–99.CrossRefGoogle Scholar
  5. 5.
    Fishman J, Rubin R, Koziel M, Periera B. Hepatitis C virus and organ transplantation. Transplantation. 1996;62:147–54.CrossRefGoogle Scholar
  6. 6.
    David R. Snydman, Section Editor. Special section: infections in transplantation and other immunocompromised hosts cadaver donor screening for infectious agents in solid organ transplantation Francis L. Delmonico New England Organ Bank and Harvard Medical School, Newton, Massachusetts. Google Scholar
  7. 7.
    Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, et al. Long-term follow up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91:1265–72.CrossRefGoogle Scholar
  8. 8.
    Lai JC, O’Leary JG, Trotter JF, Verna EC, Brown RS Jr, Stravitz RT, et al. For Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multi-center cohort study. Liver Transpl. 2012;18:532–8.CrossRefGoogle Scholar
  9. 9.
    Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis. 2012;60:112–20.CrossRefGoogle Scholar
  10. 10.
    Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis. 2012;60:112–20.CrossRefGoogle Scholar
  11. 11.
    Stepanova M, Sayiner M, de Avila L, Younossi Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16:137.CrossRefGoogle Scholar
  12. 12.
    Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C–positive kidneys. N Engl J Med. 2015;373:30–305.CrossRefGoogle Scholar
  13. 13.
    Israni AK, Zaun D, Bolch C, Rosendale JD, Schaffhausen C, Snyder JJ, et al. OPTN/SRTR 2015 annual data report: deceased organ donation. Am J Transplant. 2017;17(suppl 1):503–42.CrossRefGoogle Scholar
  14. 14.
    Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10- year update. J Hear Lung Transplant. 2016;35:1–23.CrossRefGoogle Scholar
  15. 15.
    Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shaked A, Nunes F, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73:582–7.CrossRefGoogle Scholar
  16. 16.
    Seem DL, Lee I, Umscheid CA, Kuehnert MJ. PHS Guideline for reducing Human Immunodeficiency Virus, Hepatitis B virus, and Hepatitis C virus transmission through organ transplantation. Public Health Reports. 2013;128(4):247–343.Google Scholar
  17. 17.
    Gordon EJ, Mullee J, Beauvais N, Warren E, Theodoropoulos N, McNatt G, et al. Education and informed consent about increased risk donor kidneys: a national survey of non-physician transplant providers. Transpl Infect Dis. 2014;16(2):251–60.CrossRefGoogle Scholar
  18. 18.
    OPTN Policy 2.9 Required deceased donor infectious disease testing,
  19. 19.
    Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1188–200.CrossRefGoogle Scholar
  20. 20.
    Kling CE, Limaye AP, Sibulesky L. Changing landscape of hepatitis C virus-positive donors. World J Hepatol. 2017;9(20):905–6.CrossRefGoogle Scholar
  21. 21.
    Kucirka LM, Bowring MG, Massie AB, Luo X, Nicholas LH, Segev DL. Landscape of deceased donors labeled increased risk for disease transmission under new guidelines. Am J Transplant. 2015;15(12):3215–23.CrossRefGoogle Scholar
  22. 22.
    Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief, no 294. Hyattsville, MD: National Center for Health Statistics. 2017/CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at
  23. 23.
    Gonzalez SA, Trotter JF. The rise of the opioid epidemic and hepatitis C positive organs: A new era in liver transplantation. Hepatology. 2017;67(4):1600–1608.Google Scholar
  24. 24.
    Duan KI, Englesbe MJ, Volk ML. Centers for disease control ‘high-risk’ donors and kidney utilization. Am J Transplant. 2010;10(2):416–20.CrossRefGoogle Scholar
  25. 25.
    Volk, ML, Wilk, A, Wolfe, C, Kaul, DR, The ‘PHS increased risk’ label is associated with non-utilization of hundreds of organs per year, (presentation, American Transplant Congress. Boston, MA, 2016).Google Scholar
  26. 26.
    Understanding the risk of transmission of HIV, hepatitis B, and hepatitis C from U.S. PHS Increased Risk Donors. Guidance document.
  27. 27.
    Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1176–87.CrossRefGoogle Scholar
  28. 28.
    Ison, MG, Risky business: does all risky behavior increase risk equally, Presentation, American Transplant Congress, Philadelphia, PA, May 5, 2015.Google Scholar
  29. 29.
    Kakizoe Y, Nakaoka S, Catherine A, Beauchemin A, Morita S, Mori H, et al. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV strain. Sci Rep. 2015;5:10371.CrossRefGoogle Scholar
  30. 30.
    Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29(3):908–14.CrossRefGoogle Scholar
  31. 31.
    Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Ifect Dis. 2005;40(7):951–8.CrossRefGoogle Scholar
  32. 32.
    Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis. 2006;43(10):1277–83.CrossRefGoogle Scholar
  33. 33.
    McHutchinson JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002;35(3):688–93.CrossRefGoogle Scholar
  34. 34.
    Whitcomb E, Choi WT, Jerome KR, Cook L, Landis C, Ahn J, Te HS, et al. Biopsies from allograft liver contain histologic features of hepatitis C virus infection following virus eradication. Clin Gastroenterol Hepatol. 2017;15(8):1279–85.Google Scholar
  35. 35.
    • Elmasry S, Wadhwa S, Bang BR, Cook L, Chopra S, Kanel G, et al. Detection of occult hepatitis C infection in patients who achieved a sustained virologic response to direct-actingantiviral agents for recurrent infection after liver transplantation. Gatroenterology. 2017;152(3):550–553.e8 This is an important study as it is a prospective study demonstrating the presence of occult HCV infection in some patients with abnormal levels of serum aminotransferases, despite SVR12 to DAAs after liver transplantation. CrossRefGoogle Scholar
  36. 36.
    Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21(7):447–51.CrossRefGoogle Scholar
  37. 37.
    Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the global burden of disease: a need to regroup. J Viral Hepat. 2013;20:600–1.CrossRefGoogle Scholar
  38. 38.
    Andrew Hill, Bryony Simmons, Jawaad Saleem, Graham Cooke. Risk of late relapse or re-infection with hepatitis C after virologic response: metanalysis of 66 studies. Conference on Retroviruses and Opportunistic Infections 2015.Google Scholar
  39. 39.
    Einav S, Koziel MJ. Immunopathogenesis of hepatitis C virus in the immunosuppressed host. Transpl Infect Dis. 2002;4(2):85–92.Google Scholar
  40. 40.
    Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21(7):447–51.CrossRefGoogle Scholar
  41. 41.
    Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci. 2014;8(1):19–25.CrossRefGoogle Scholar
  42. 42.
    Moorman AC, Drobenuic J, Kamili S. Prevalence of false-positive hepatitis C antibody results, national health and nutrition examination study (NHANES) 2007–2012. J Clin Virol. 2017;89:1–4. Scholar
  43. 43.
    Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of hcv infection by interferon therapy. Clin Infect Dis. 2005;40(6):e49–54.CrossRefGoogle Scholar
  44. 44.
    Yusuke Kakizoe, Shinji Nakaoka, Catherine A. A. Beauchemin, Satoru Morita, Hiromi Mori, Tatsuhiko Igarashi, Kazuyuki Aihara, Tomoyuki Miura, and Shingo Iwami. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV.Google Scholar
  45. 45.
    Hajarizadeh, B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, et al. Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 Study. J Viral Hep. 2015;22(9):708–17.Google Scholar
  46. 46.
    Organ procurement and transplantation network. National Data.https://optn.transplant.hrsa.goc/data/view-data-reports/national-data/ #. Accessed 2017.
  47. 47.
    Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedwald J, Friedman J et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant 2017;17(11): 2790–2802.Google Scholar
  48. 48.
    •• Suryaprasad A, Basavaraju SV, Hocevar SN, Theodoropoulos N, Zuckerman RA, Hayden T, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. Am J Transplant. 2015;15:1827–35 This study is relevant as it is the first study reporting newly detected donor-derived HCV after transplantation in organ recipients from increased risk donors.CrossRefGoogle Scholar
  49. 49.
    •• Bari K, Luckett K, Kaiser T, Diwan T, Cuffy M, Schoech M, et al. Hepatitis C transmission from seropositive, non-viremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2017. This study is important as it the first prospective study looking at HCV transmission in HCV-negative recipients of HCV antibody-positive NAT-negative organs.
  50. 50.
    Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol. 2014;20(32):11095–115.CrossRefGoogle Scholar
  51. 51.
    Hori T, Onishi Y, Kamei H, Kurata N, Ishigami M, Ishizu Y, et al. Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol. 2016;29(4):454–9.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Kwo PY. Direct acting antiviral therapy after liver transplantation. Curr Opin Gastroenterol. 2016;32:152–8.PubMedGoogle Scholar
  53. 53.
    Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533–40. Scholar
  54. 54.
    Chute DF, Chung RT, Sise ME. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. Kidney Int. 2018;93(3):560–7.CrossRefGoogle Scholar
  55. 55.
    Brown K. Maximizing donors with viral hepatitis in the current era. Liver Transplant 2017;23(S1): S44–49.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology and Hepatology, Department of MedicineHenry Ford HospitalDetroitUSA

Personalised recommendations